Biomerica (BMRA) Cash & Equivalents (2010 - 2026)

Biomerica has disclosed Cash & Equivalents across 17 years of filings, most recently posting $1.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $1.3 million, down 56.31% year-over-year; the trailing twelve-month figure through Feb 2026 was $1.3 million (down 56.31% YoY), and the FY2025 annual result was $3.1 million, down 26.67% from the prior year.
• Cash & Equivalents came in at $1.3 million for Q1 2026 at Biomerica, down from $2.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $10.2 million in Q1 2022 to a low of $1.3 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $4.2 million (2024), against an average of $4.9 million.
• Across the five-year window, Cash & Equivalents surged 92.96% in 2022 and slumped 67.12% in 2023, its largest moves.
• Biomerica's Cash & Equivalents stood at $5.1 million in 2022, then jumped by 40.81% to $7.1 million in 2023, then tumbled by 66.75% to $2.4 million in 2024, then grew by 7.21% to $2.5 million in 2025, then plunged by 47.46% to $1.3 million in 2026.
• The last three Cash & Equivalents figures came in at $1.3 million (Q1 2026), $2.5 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.